Search for: "State of IN v. Amgen, Inc., et al"
Results 61 - 75
of 75
Sorted by Relevance
|
Sort by Date
13 May 2009, 8:00 pm
Amgen Inc. v. [read post]
2 Jan 2019, 10:26 am
Delta Airlines Inc., et al., the 11th Circuit noted that, “while Fifth Third may have changed the legal analysis of our prior decision, it does not alter the outcome. [read post]
9 Aug 2012, 5:00 am
United States Surgical Corp. [read post]
2 Mar 2012, 6:52 am
United States Surgical Corp. [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram)… [read post]
4 Aug 2022, 7:54 pm
Pfizer, Inc. v. [read post]
4 Apr 2008, 1:00 am
, (Ars Technica), (Patent Prospector), (Washington State Patent Law Blog), (IP Law Observer), (PLI), (PLI), (IP Updates), (Patent Docs), (Peter Zura’s 271 Patent Blog), (The Invent Blog), (IP Spotlight), (Just a Patent Examiner), (Techdirt), (Patent Baristas), (IPBiz), (IPBiz), (Patently-O), (IAM), (IP ThinkTank), (Against Monopoly), (Against Monopoly), (IP Law360), (Hal Wegner), (Ladas & Parry), Global Global - General Virtual monopoly – four strategic… [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’… [read post]
13 Sep 2013, 1:31 pm
Wal-Mart including an analysis of the Supreme Court’s decisions in Amgen Inc. v. [read post]
8 Feb 2008, 7:00 pm
– Facebook’s contractual rights to users’ photos problematic: (Spicy IP)PharmaEuropean Commission probes pharmaceutical sector: (Philip Brooks),WHO Board sets course on IP, avian flu, tighter publication policy: (Intellectual Property Watch),India: The Competition Act, patents and over hyped drugs: (Part I - Spicy IP), (Part II – Spicy IP), (Part III – Spicy IP),Ignoring not the solution –… [read post]
19 Feb 2011, 3:32 pm
§ 282, or the "rebuttable presumption that different claims are of different scope," Amgen Inc. v. [read post]
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge), (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v Apotex:… [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
25 Jan 2024, 6:32 am
The FTC also touted its settlement of the Amgen/Horizon matter (here and here) although, as I explained in December, the core of the consent order—reached on the eve of trial—had been proposed by Amgen all along. [read post]
9 Aug 2007, 5:53 am
United States v. [read post]
